Loading
A phase 1/2 trial of Super DC Vaccine in advanced solid tumours, run by Shanghai Cell Therapy Group Co.,Ltd, now recruiting.
Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors is a phase 1/2 interventional study registered as NCT07146672 by Shanghai Cell Therapy Group Co.,Ltd, with 12 participants planned, started 2025-07-31 and due to reach its primary completion in 2026-12-31. Interventions recorded: Super DC Vaccine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/